Patient demographics and baseline characteristics
| PEP | HFCWO | |
|---|---|---|
| Number of subjects | 51 | 56 |
| Median age (years) | 12 (range 6–41) | 11 (range 6–47) |
| Age 6–11 years | 25 | 31 |
| Age 12–17 years | 18 | 14 |
| Age 18–47 years | 8 | 11 |
| Female/male | 25/26 | 25/31 |
| Pseudomonas positive/negative | 17/34 | 19/37 |
| FVC percent predicted | 100.7±13.8 | 94.3±14.8 |
| FEV1 percent predicted | 92.9±17.2 | 85.8±18.0 |
| FEF25–75 percent predicted | 79.7±31.6 | 73.8±32.5 |
| Body mass index | 18.43±3.37 | 18.62±4.55 |
| Delta F508 homozygous | 47% | 43% |
| Regular use of inhaled bronchodilator | 88% | 88% |
| Regular use of hypertonic saline | 12% | 13% |
| Regular use of rhDNase | 25% | 30% |
| Regular use of inhaled steroids | 55% | 48% |
| Regular use of an inhaled antibiotic | 24% | 20% |
| Regular use of azithromycin | 19% | 14% |
| Number of patients performing ACT once daily | 12 | 12 |
Data for body mass index, FVC, FEV1 and FEF25–75 are represented as mean±SD.
ACT, airway clearance technique; FEF25–75, forced expiratory flow between 25% and 75% of vital capacity; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; HFCWO, high frequency chest wall oscillation; PEP, positive expiratory pressure.